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358Outcome of Transplantation for Myelofibrosis
Karen K. Ballen,1 Smriti Shrestha,2 Kathleen A. Sobocinski,2 Mei-Jie Zhang,3 Asad Bashey,4
Brian J. Bolwell,5 Francisco Cervantes,6 Steven M. Devine,7 Robert Peter Gale,8 Vikas Gupta,9
Theresa E. Hahn,10 William J. Hogan,11 Nicolaus Kro¨ger,12 Mark R. Litzow,11
David I. Marks,13 Richard T. Maziarz,14 Philip L. McCarthy,10 Gary Schiller,15
Harry C. Schouten,16 Vivek Roy,17 Peter H. Wiernik,18 Mary M. Horowitz,2
Sergio A. Giralt,19 Mukta Arora20Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small series
have reported long-term disease-free survival (DSF) after allogeneic hematopoietic cell transplantation
(HCT). In this study, we analyze the outcomes of 289 patients receiving allogeneic transplantation for primary
myelofibrosis between 1989 and 2002, from the database of the Center for International Bone Marrow
Transplant Research (CIBMTR). The median age was 47 years (range: 18-73 years). Donors were HLA iden-
tical siblings in 162 patients, unrelated individuals in 101 patients, and HLA nonidentical family members in 26
patients. Patients were treated with a variety of conditioning regimens and graft-versus-host disease (GVHD)
prophylaxis regimens. Splenectomy was performed in 65 patients prior to transplantation. The 100-day
treatment-related mortality was 18% for HLA identical sibling transplants, 35% for unrelated transplants,
and 19% for transplants from alternative related donors. Corresponding 5-year overall survival (OS) rates
were 37%, 30%, and 40%, respectively. DFS rates were 33%, 27%, and 22%, respectively. DFS for patients re-
ceiving reduced-intensity transplants was comparable: 39% for HLA identical sibling donors and 17% for un-
related donors at 3 years. In this large retrospective series, allogeneic transplantation for myelofibrosis
resulted in long-term relapse-free survival (RFS) in about one-third of patients.
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Myelofibrosis (agnogenic myeloid metaplasia; pri-
mary myelofibrosis) is a clonal myeloproliferative dis-
order, characterized by inefficient hematopoiesis and
bonemarrow (BM) fibrosis [1]. The disease can present
de novo (primary myelofibrosis) or following a previ-
ously known polycythemia vera or essential thrombo-
cythemia. Clinical manifestations include anemia,
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g/dL, WBC\4 or.30 109/L, and peripheral blasts
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JAK-2 kinase, interleukin-8, transforming growth fac-
tor B, and impaired GATA-1 expression in the devel-
opment of the disease and in an effort to improve
classification and prognostic assessment [7-9].
There are several treatment approaches for pa-
tients with myelofibrosis. The median age at diagnosis
is 67 years, andmany elderly patients aremanagedwith
supportive care. Erythropoietin has been helpful for
the treatment of anemia in some patients, and
hydroxyurea has been used to control the WBC count
[10]. Thalidomide combined with prednisone has been
tested in a Phase II trial; 62% of patients had improve-
ment in anemia [11]. Interferon therapy has been effec-
tive in decreasing splenomegaly, but side effects limit
its use [12]. Other therapies include thalidomide deriv-
atives, androgens, cladarabine, and splenectomy [13].
Currently, the role of JAK2 inhibitors is being investi-
gated [14]. However, none of these treatment strate-
gies are curative.
The only known treatment for myelofibrosis that
has been shown to have curative potential is allogeneic
hematopoietic cell transplantation (HCT). Several
reports have shown survival rates of 40% to 60% after
allogeneic transplantation. Guardiola and colleagues
[15] reported a 47% 5-year probability of survival in
a study of 55 patients. The Canadian group reported
on 25 patients, with a projected 2-year overall survival
(OS) of 41% [16]. Deeg and colleagues [17,18] have
reported a 3-year survival of 58%. Several small series
of older patients transplanted with reduced-intensity
conditioning (RIC) regimens have shown encouraging
results, with decreased treatment-related mortality
(TRM) [19,20].
In this study, we examine the outcome of 289 pri-
mary myelofibrosis patients receiving allogeneic HCT
from 1989 to 2002. This data set represents the largest
series of patients transplanted for myelofibrosis and
allows identification of prognostic indicators.PATIENTS AND METHODS
Data Sources
The Center for International Blood and Marrow
Transplant Research (CIBMTR) is a research affilia-
tion of the International Bone Marrow Transplant
Registry (IBMTR), Autologous Blood and Marrow
Transplant Registry (ABMTR), and the National
Marrow Donor Program (NMDP) that comprises
a voluntary working group ofmore than 500 transplant
centers worldwide. Participating centers contribute
detailed data on consecutive allogeneic and autologous
HCT to a Statistical Center at the Medical College of
Wisconsin. Demographic and clinical data are
collected on a representative sample of patients in
the registry using a weighted randomization scheme.Participating centers are required to report all consec-
utive transplant data; compliance is monitored by
on-site audits. Patients are followed longitudinally,
with yearly follow-up.
The CIBMTR collects data at 2 levels: registration
and research. All CIBMTR teams contribute registra-
tion data. Research data are collected on subsets of reg-
istered patients and include comprehensive pre- and
posttransplant clinical information. Computerized
checks for errors, physician reviews of submitted
data, and on-site audits of participating centers
improve the quality of data. Observational studies con-
ducted by the CIBMTR are done by a waiver of in-
formed consent and in compliance with HIPAA
regulations as determined by the institutional review
board (IRB) and the Privacy Officer of the Medical
College of Wisconsin.
Eligible Patients
Patients with primary myelofibrosis who under-
went a first allogeneic BM or peripheral blood stem
cell transplant (PBSCT) using an HLA matched sib-
ling donor, unrelated donor (URD), or alternative re-
lated donor between the years 1989 and 2002 were
eligible if reported to the CIBMTR. Data were re-
ported by 118 teams from 29 countries. Patients with
myelofibrosis progressing to acute leukemia (.30%
BM myeloblasts) were excluded from this analysis.
There were 6 patients with BMmyeloblast percentage
between 20% and 30%. Patients who had progressed
to myelofibrosis from polycythemia vera or essential
thrombocythemia were also excluded. All surviving
recipients receiving a transplant from a URD included
in this analysis were retrospectively contacted and
provided informed consent for participation in the
NMDP. Informed consent for retrospective data anal-
ysis was waived by the NMDP IRB for all deceased pa-
tients. The NMDP IRB had only 1 member affiliated
with the NMDP. Surviving participants who did not
provide informed consent to allow analysis of clinical
data were excluded. Three patients were excluded by
this corrective action plan. To adjust for the potential
bias introduced by exclusion of nonconsenting surviv-
ing patients, a corrective action plan (CAP)-modeling
process randomly excluded approximately the same
percentage of deceased patients using a biased coin
randomization with exclusion probabilities based on
characteristics association with not providing consent
for use of the data in survivors [21].
Endpoints
Primary endpoints were hematopoietic recovery,
acute graft-versus-host disease (aGVHD), chronic
GVHD (cGVHD), OS, and response. Hematopoietic
recovery was defined as time to neutrophils (absolute
neutrophil count [ANC]) .0.5  109/L for 3
360 Biol Blood Marrow Transplant 16:358-367, 2010K. K. Ballen et al.consecutive days and time to platelets $20  109/L.
aGVHD was defined as the occurrence of grade II,
III, or IV skin, gastrointestinal (GI), or liver abnormal-
ities fulfilling the Glucksberg criteria of aGVHD [22].
cGVHDwas the occurrence of symptoms in any organ
system fulfilling the criteria of cGVHD. OS was de-
fined as the time to death. Patients were censored at
time of last follow-up. Graft failure was defined by
no neutrophil engraftment by day 35. Response and
treatment failure, when possible, were defined accord-
ing to the criteria of Guardiola et al: (1) hematologic
remission (normal PB counts, disappearance of symp-
toms, splenomegaly, and cytogenetic abnormalities),
(2) complete histohematologic remission (hematologic
remission plus disappearance of the marrow fibrosis),
(3) partial histohematologic remission (hematologic
remission plus partial reduction of marrow fibrosis),
and (4) treatment failure (disease recurrence or persis-
tence) [15]. Disease free survival (DFS) was considered
a continuous complete hematologic remission after
transplant.Statistical Analysis
Descriptive tables of patient-, disease-, and
treatment-related factors list median and range for
continuous variables and percent of total for cate-
goric variables. The product-limit estimator pro-
posed by Kaplan-Meier was used to estimate the
median and range of the follow-up time. Probabilities
of DFS and OS were calculated using the Kaplan-
Meier estimator, with the variance estimated by
Greenwood’s formula. Variables for other endpoints
were generated using cumulative incidence estimates
[23]. Comparison of survival curves was done using
the log-rank test. Multivariate analyses were per-
formed using proportional hazards models. These
analyses fit models to determine which risk factors
may be related to a given outcome. All variables
were first examined to assure that they comply with
the proportional hazards assumption. Factors found
to have nonproportional hazards were adjusted in
subsequent analyses. A stepwise model building ap-
proach was used to develop models for relapse,
TRM, DFS, and OS. A CAP modeled data set was
used in this article. No further statistical adjustments
were made. This CAP modeling procedure was re-
viewed and approved by the NMDP IRB. The cor-
rective action plan was submitted to the Office for
Human Research Protection (OHRP) and approved
by the division of compliance oversight. This meth-
odology has been extensively used and published by
all studies from the CIBMTR using the NMDP data-
sets. The CAP model was developed on a sample of
3693 survivors, of which 2966 (80.3%) had given
consent to have their data used. The predictive model
for consent included indicators of age group, disease,stem cell source, patient cytomegalovirus (CMV) sta-
tus, and sex, and had an area under the curve (AUC)/
C statistic of 0.75.RESULTS
Patient and Disease-Related Characteristics
Table 1 outlines the characteristics of patients re-
ceiving allogeneic transplants formyelofibrosis. All pa-
tients were reported by the transplant center as having
primary myelofibrosis, without prior polycythemia
vera or essential thrombocythemia. One hundred
sixty-two recipients underwent an HCT from HLA
identical sibling donors, 101 from URD, and 26 pa-
tients from other related donors. The median ages at
transplantation for these 3 groups were 45 years,
49 years, and 46 years, respectively. The majority of
patients had moderate or severe fibrosis in the BM at
the time of transplant, as graded by the transplant cen-
ter. There was no uniform assessment ofmarrow fibro-
sis. Nine patients had an elevated WBC count of
.30,000/mL and a hemoglobin of \10 g/dL at the
time of transplant. Splenectomy had been performed
in 18% of the identical sibling recipients, 38% of the
URD patients, and 13% of the patients receiving alter-
native related donor transplants. Among the patients
without a splenectomy, 58% of the identical sibling re-
cipients, 68% of the URD recipients, and 40% of the
other related donor recipients had splenomegaly at
the time of transplantation. The presence of spleno-
megaly was reported by the transplant center, and
may have been based on physical examination or radio-
graphic findings, or both. The median follow-up was
41, 48, and 46 months, respectively. The indication
for transplantation was not ascertained on the
CIBMTR forms. Thirty-two percent of patients had
a Lille score of 0, 36% a Lille score of 1, and 31%
a Lille score of 2.
Transplant characteristics are outlined in Table 1.
The majority of patients received BM as a source of
stem cells. Thirty percent of the identical sibling trans-
plantations, 62% of the URD transplantations, and
23% of the other related donor transplantations were
performed with total body radiation (TBI) as part of
the conditioning regimen. The majority of patients re-
ceived a myeloablative (MA) conditioning regimen. T
cell depletion was used in \5% of patients in all
groups. For the purpose of classification of
HLA matching, the new classification system pro-
posed by Wesidorf et al. [24] for retrospective studies
was used.TRM
At 100 days, the TRM was 18% for the identical
sibling transplants, 35% for the URD patients, and
Table 1. Characteristics of Adult Patients ReceivingAllogeneic Transplantation between 1989 and 2002 forMyelofibrosis Reported
to the CIBMTR
Variables N eval Identical Sibling N eval Other related N eval Unrelated
Number of patients 162 26 101
Age at transplant, N (%) 162 45 (18-73) 26 46 (20-65) 101 49 (18-70)
<45 years 80 (49) 12 (46) 33 (33)
$45 years 82 (51) 14 (54) 68 (67)
Male sex, N (%) 162 101 (62) 26 18 (69) 101 60 (59)
Karnofsky score prior to transplant 158 25 97
<90 63 (40) 9 (36) 49 (51)
$90 95 (60) 16 (64) 48 (49)
Blast in peripheral blood prior to transplant, N (%) 140 50 (36) 17 8 (47) 90 43 (48)
Splenectomy prior to transplant, N (%) 153 27 (18) 23 3 (13) 92 35 (38)
Splenomegaly prior to transplant, N (%) (Among patients without splenectomy) 126 73 (58) 20 8 (40) 57 39 (68)
Time from diagnosis to transplant, median(range) in months 162 11 (1-196) 26 11 (2-157) 101 13 (1-284)
<24 months 113 (70) 19 (73) 66 (65)
$24 months 49 (30) 7 (27) 35 (35)
Cytogenetics prior to transplant, N(%) 61 8 27
Normal 32 (52) 5 (63) 13 (48)
Abnormal 29 (48) 3 (37) 14 (52)
Hemoglobin prior to transplant, N (%) 133 20 64
<10 g/dL 75 (56) 15 (75) 34 (53)
$10 g/dL 58 (44) 5 (25) 30 (47)
Graft type, N (%) 162 26 101
BM 95 (59) 14 (54) 74 (73)
PBSC/BM + PBSC 67 (41) 12 (46) 27 (27)
WBC count, N(%) 153 22 70
#30,000/ mL 143 (93) 22 (100) 59 (84)
>30,000/mL 10 (7) — 11 (16)
Conditioning regimens types N (%) 162 26 101
Cy+tbi±others 41 (25) 6 (23) 43 (42)
By+cy 86 (53) 16 (62) 23 (23)
Flu + TBI 2 (1) — 12 (12)
Flu+other 2 (1) — 1 (1)
Bu 16 (10) 3 (11) 8 (8)
Mel 6 (4) 1 (4) 6 (6)
TBI 4 (3) — 8 (8)
Others 5 (3) — —
Conditioning regimen, N (%) 162 26 101
TBI 48 (30) 6 (23) 63 (62)
Non-TBI 114 (70) 20 (77) 38 (38)
Regimen types, N (%) 162 26 101
Ablative 134 (83) 23 (88) 72 (71)
Nonmyeloblative/reduced intensity 28 (17) 3 (12) 29 (29)
ATG given as conditioning or GVHD prophylaxis 162 26 101
No 144 (89) 20 (77) 79 (78)
Yes 18 (11) 6 (23) 22 (22)
GVHD prophylaxis 162 26 101
MTX + CsA ± other 102 (62) 12 (46) 54 (53)
MTX ± other 1 (1) — —
FK506± other 18 (11) 2 (8) 25 (25)
CsA ± other 36 (22) 6 (23) 19 (19)
T-depletion ± other 3 (2) 1 (4) 2 (2)
Cortico ± other 1 (1) — —
Other or none 1 (1) 5 (19) 1 (1)
Year of transplant, N (%) 162 26 101
1989-1995 55 (34) 5 (19) 13 (13)
1996-2002 107 (66) 21 (81) 88 (87)
HLA matching NA 26 101
Well matched — 38 (37)
Partially matched 5 (19) 34 (34)
Mismatched 14 (54) 19 (19)
HLA data missing 7 (27) 10 (10)
Median (range) follow-up, months 162 41 (3-144) 26 46 (12-118) 101 48 (4-124)
EVAL indicates evaluable; BM, bonemarrow; PBSC, peripheral blood stem cells; TBI, total body irradiation; Hb, hemoglobin; Cy, cyclophosphamide; CsA,
cyclosporine; Bu, busulfan; Flu, fludarabine; Mel, melphalan; FK506, tacrolimus; MTX, methotrexate; ATG, antithymocyte globulin; GVHD, graft-versus-
host disease; WBC, white blood cell; CIBMTR, Center for International Blood and Marrow Transplant Research.
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identical sibling transplants, TRM was 27% at 1 year,
and 35% at 5 years. TRM was 24% at 1 year and 38%
at 5 years for patients using a related donor graft notfrom an HLA identical sibling. The URD patients,
as expected, experienced higher TRM (P 5 .02 at
5 years for HLA identical siblings versus URDs).
TRM was 43% at 1 year, and 50% at 5 years in this
362 Biol Blood Marrow Transplant 16:358-367, 2010K. K. Ballen et al.group. TRM, relapse rate, DFS, and OS are presented
in Table 2. TRM by donor type is summarized in
Figure 1.Engraftment
Neutrophil engraftment occurred in 95% of the
matched sibling patients at a median of 18 days. The
engraftment rate was lower for alternative donor pa-
tients, 73% for patients receiving grafts from other
related donors, and 83% for patients receiving grafts
from URD. Thirty-two patients did not achieve an
ANC of 500; 17 of these patients were URD trans-
plant, 8 HLA identical sibling, and 7 other related
donors transplant recipients. Platelet engraftment oc-
curred at a median of 27 days. Graft failure occurred
in 9% of the patients receiving grafts from HLA iden-
tical group, 27% from other related group, and 20%
from the URD group. Thus, graft failure is an impor-
tant limitation of transplantation from alternative do-
nors in this disease. Graft failure rate was not
increased in patients with splenomegaly. Graft failure
was seen in 13.3% of patients with splenomegaly ver-
sus 13.2% in those patients without splenomegaly.
However, the determination of splenomegaly may
have been suboptimal as splenomegaly was reported
by transplant centers as being present or absent. The
size of the spleen and the method for determining
splenomegaly was not reported. The graft failure rate
was 15.3% for patients who had a prior splenectomy.
The median time to engraftment was not significantlyTable 2. Survival Analysis of Transplant Outcomes among Patients
for Myelofibrosis Reported to the CIBMTR
Identical Sibling
Outcomes N eval Probability (95%CI) N eva
ANC500 @ 100 days 162 95 (91-98)% 26
PLT20 @ 12 months 159 79 (72-85) % 26
aGVHD@ 100 days 162 43 (35-50) % 25
cGVHD @ 24 months 161 40 (32-48) % 26
Relapse 160 25
@ 1 year 25 (18-32)%
@ 3 years 28 (21-35)%
@ 5 years 32 (24-41)%
TRM 160 25
@ 100 days 18 (12-24)%
@ 1 year 27 (20-34)%
@ 3 years 32 (25-40)%
@ 5 years 35 (27-43)%
DFS 160 25
@ 1 year 48 (40-56)%
@ 3 years 40 (32-48)%
@ 5 years 33 (25-42)%
Survival probability 162 26
@ 1 year 54 (46-62)%
@ 3 years 44 (36-52)%
@ 5 years 37 (26-46)%
EVAL indicates evaluable; TRM, treatment-related mortality; DFS, disease-free
versus host disease; ANC500, neutrophil engraftment; PLT20, platelets; CIBMT
confidence interval.different in patients with or without splenomegaly (19
days versus 17 days, respectively). Seven patients re-
ceived a second transplant for graft failure.
GVHD
Grade II-IV aGVHD occurred in 43% of matched
sibling patients, 40% of URD patients, and 24% of
other related donors (Figure 2). cGVHDwas reported
in 40% of matched sibling patients, 32% of URD
patients, and 23% of other related donors. There was
no effect of GVHD on relapse or survival. Only 7
patients were reported as receiving donor lymphocyte
infusions (DLIs; 5 from matched sibling donors and 2
from URD); 4 of these patients (all matched siblings)
died of disease progression.
Relapse Rate
Relapse rates are summarized in Table 2. At 1 year
after HCT, the cumulative incidence of relapse was
25%, 21%, and 12% in recipients of HLA identical
sibling donor, URD, or alternative donor transplants,
and increased to 32%, 23%, and 40%, respectively, at
5 years posttransplant (P value of .65 forHLA identical
siblings versus other donors). Disease relapses con-
tinue to occur beyond 3 years in some patients. Relapse
by donor type is summarized in Figure 2.
DFS and OS
Probability of OS at 1 year was 54%, 41%, and
60% in the HLA-identical sibling, URD, and otherReceiving Allogeneic Transplantation between 1989 and 2002
Other Related Unrelated
l Probability (95% CI) N eval Probability (95% CI)
73 (56-87) % 101 83 (76-90) %
54 (35-72) % 98 59 (49-69) %
24 (10-42) % 99 40 (31-50) %
23 (10-41) % 101 32 (23-41) %
100
12 (2-28)% 21 (13-29)%
18 (5-38)% 23 (15-32)%
40 (11-74)% 23 (15-32)%
100
19 ( 5-38)% 35 (26-44)%
24 ( 9-44)% 43 (33-53)%
38 (17-62)% 48 (38-58)%
38 (17-62)% 50 (39-61)%
100
64 (43-82)% 37 (27-47)%
43 (21-67)% 29 (20-39)%
22 (1-59)% 27 (18-37)%
101
60 (39-79)% 41 (31-51)%
40 (19-63)% 33 (23-43)%
40 (19-63)% 30 (20-40)%
survival; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft
R, Center for International Blood and Marrow Transplant Research; CI,
Figure 1. Cumulative incidence of nonrelapse mortality after receiving
allogeneic HCT by donor type for myelofibrosis reported to the
CIBMTR between 1989 and 2002.
Figure 3. Survival probability of adult patients receiving allogenic trans-
plantation (HLA identical sibling donor and unrelated donor) for myelo-
fibrosis reported to the CIBMTR between 1989 and 2002.
Biol Blood Marrow Transplant 16:358-367, 2010 363Transplant for Myelofibrosisrelated transplants, respectively. OS is outlined in
Figure 3. Probability of OS at 5 years posttransplanta-
tion was 37%, 30%, and 40%, respectively (P5 .94 for
HLA identical sibling versus other donor transplants).
Probability of DFS at 5 years was comparable among
the different donor groups at 33%, 27%, and 22%
for HLA-identical sibling, URD, and other related
transplants, respectively, P 5 .64 for HLA identical
siblings versus other donors.Causes of Death
The causes of death posttransplantation are listed
in Table 3. Causes of death were provided by the trans-
plant centers. The primary cause of death in the HLA
identical sibling patients was progressive disease, fol-
lowed by infection and organ failure. In the URD
patients, the most common cause of death was infec-
tion, followed by GVHD. Patients who died of infec-
tion may also have had GVHD; 17 of 35 patients who
died of infection also were reported as having GVHD.
For the other related donor group, the most common
causes of death were progressive disease and organ fail-
ure. Deaths from graft failure may be difficult to ascer-
tain, as many of these patients may be coded as dying of
infection.Figure 2. Cumulative incidence of relapse after receiving allogeneic
HCT by donor type for myelofibrosis reported to the CIBMTR between
1989 and 2002.Predictors for Superior DFS
Multivariate analysis was performed for patients
receiving transplant from HLA-identical sibling and
URDs. Table 4 lists the variables examined in the
multivariate model. The final multivariate model is
illustrated in Table 5. In multivariate analysis, perfor-
mance status\90% (relative risk [RR] 1.41 [95% CI,
1.04-1.92], P 5 .0284) and the presence of PB blasts
(RR 1.75 [95% CI 1.24-2.47], P 5 .0013) predicted
for worse DFS. Patients who received a transplant
from a URD had a trend toward lower DFS. DFS
for recipients of URD transplant with poor Karnofsky
score and PB blasts was 29% and 15% at 1 year and 3
years, respectively (Figure 4). Among 56 patients with
favorable risk factors (HLA identical sibling donor,
performance status $90%, and no PB blasts) 1- and
3-year probabilities of survival were 69% and 60%,
respectively (Figure 5). WBC count, splenomegaly,
hemoglobin at transplant, and a prior splenectomy
were not predictive of DFS. The Lille score was avail-
able on 198 patients. There was no difference in DFS
based on Lille score.RIC/Nonmyeloablative Transplants
Seventeen percent of the HLA identical sibling
donor recipients and 29% of the URD recipients
received RIC or nonmyeloablative (NMA) condition-
ing transplants. Conditioning regimens were catego-
rized as RIC or NMA using consensus criteria
proposed by the Regimen-Related Toxicity Working
Committee of the CIBMTR. Regimens employing
TBI#500 cGy as a single fraction or#800 cGy if frac-
tionated, busulfan (Bu) doses#9 mg/kg, or melphalan
(Mel) doses #150 mg/m2 were categorized as RIC.
Regimens using fludarabine (Flu) without Bu and/or
Mel and regimens using TBI doses of 200 cGy (with
or without Flu) were categorized as NMA. Regimens
that did not fit these criteria were assigned by the au-
thors based on recommendations of the Regimen-Re-
lated Toxicity Working Committee [25]. Of these, 21
Table 3. Causes of Death in Adult Patients Receiving Allo-
genic Transplantation between 1989 and 2002 for Myelofibro-
sis Reported to the CIBMTR
HLA sibs Other Unrelated
Causes of Death N (%) N (%) N (%)
Number of patients 162 26 101
Number of deaths 89 (55) 18 (69) 71 (70)
Primary disease 24 (30) 3 (17) 9 (16)
Infection 20 (25) 1 (5) 14 (25)
Interstitial pneumonitis 2 (3) — 2 (3)
GVHD 7 (9) 1 (5) 10 (18)
Organ failure 10 (12) 3 (17) 7 (12)
Graft failure — 1 (5) 2 (3)
ARDS 1 (1) — 1 (1)
Bleeding 4 (5) 2 (12) 2 (4)
Other — 2 (12) 1 (2)
Secondary malignancy 1 (1) 1 (5) —
Unknown 12 (15) 3 (17) 9 (16)
Missing 8 (9) 1 (5) 14 (20)
GVHD indicates graft-versus-host disease; ARDS, acute respiratory dis-
ease syndrome; CIBMTR, Center for International Blood and Marrow
Transplant Research.
364 Biol Blood Marrow Transplant 16:358-367, 2010K. K. Ballen et al.recipients received an NMA regimen and 39 received
an RIC regimen. A total of 21 patients received
BMT (17 RIC, 4 NMA) and 39 received a PBSCT
(22 RIC, 17 NMA). Graft failure was seen in 7 patients
(6 RIC, 1 NMA), 4 of these received a PBSCT. All of
these 7 patients died. One died of graft failure, 1 died
of organ failure, 1 died of infection, 1 died of primary
disease, and cause of death was unknown for 3 remain-
ing patients. One hundred-day TRM for the RIC sib-
ling donor transplants was 11%. One-year TRM for
these patients was 15%. DFS at 3 years was 39%,
which is comparable to that seen in the MA transplant
group. However, for the 28 URD RIC transplant re-
cipients, the TRM at 1 year was 49%, and DFS at 3
years was only 17%.Table 4. Variables Examined in the Multivariate Analysis
Patient related:
- Age (<45 years versus $45 years)
- Sex (male versus female)
- Karnofsky performance status (<90% versus $90%)
Disease related:
- Subdisease (myeloid metaplasia versus acute or myelosclerosis)
- Fibrosis in marrow prior to conditioning (Grade III
[osteomyelosclerosis] versus other)
- Peripheral blood blasts (present versus absent)
- Splenomegaly prior to conditioning (yes versus no versus splenectomy)
- Time from diagnosis to HSCT (<24 months versus $24 months)
- Cytogenetics prior to conditioning (normal versus other)
- Hemoglobin at time of transplant (<10 versus $10)
Transplant related:
- Source of stem cells (BM versus PBSC/both)
- Conditioning Regimen (TBI versus non-TBI)
- Myeloblative versus reduced-intensity conditioning or nonmyeloblative
- Year of BMT (<1996 versus $1996)
TBI indicates total body irradiation; BM, bone marrow; BMT, bone
marrow transplantation; PBSC, peripheral blood stem cells; HSCT,
hematopoietic stem cell transplantation.DISCUSSION
Allogeneic HCT is a therapeutic option for some
patients with myelofibrosis. Myelofibrosis is incurable
with standard chemotherapy. Autologous transplanta-
tion has been investigated in a small series of patients,
but is not thought to be curative for this clonal stem
cell disorder [26]. Mittal et al. [27], Ditschkowski
et al. [28], Deeg et al. [17], Guardiola et al. [15], Ker-
bauy et al. [18], and Daly et al. [16] have reported on
the results of allogeneic HCT for myelofibrosis. These
series have reported 3-year probabilities of OS of 37%
to 58%. An updated report from Seattle describes 104
patients with myeloproliferative disorders, including
62 with chronic idiopathic myelofibrosis [29]. Use of
a targeted Bu/cyclophosphamide (Cy) regimen, youn-
ger age, and low comorbidity score predicted for im-
proved survival. Patriarca and colleagues [30] have
recently reported on 100 myelofibrosis patients from
26 Italian centers. Three-year OS was 42%, with
a trend to improved survival in patients receiving
PBSCs as the graft source.
In this current study, we extend the observations
of these investigators, using the resources of the
CIBMTR. Two hundred eighty-nine adult patients
contributed data to the analysis, the largest reported
series of transplantation for myelofibrosis. The analy-
sis was hampered by its retrospective nature and
included patients treated in many transplant centers
with a variety of conditioning regimens. The majority
of patients received MA conditioning regimens, and,
as expected, had a median age lower than the median
age reported for myelofibrosis patients at diagnosis.
In addition, diagnosis was not confirmed by central
pathology review. Given the low rate of splenomegaly
(58% for patients receiving sibling donor transplants)
it is possible that some patients may have been mis-
classified at the transplant center. The definition of
response proposed by Guardiola and the International
Working Group [31] was published after many of the
transplants reported here had been performed.
Therefore, relapse and DFS data were not based on
those criteria and may be difficult to interpret. Cyto-
genetic analysis was missing for many patients. Be-
cause of missing data, Cervantes and Dupriez scores
could not be used in a multivariate analysis. Multivar-
iate analysis was not performed for the alternative
donors, because of the small sample numbers. In
addition, Jak2 kinase information was not available
on our patients, as the patients were all transplanted
before 2002.
The 3-year probability of OS was 44% for patients
receiving transplants from HLA matched sibling do-
nors, similar to outcomes reported in other series. As
expected, TRM was higher for URD recipients. Dis-
ease relapses continue to be seen beyond 3 years in
some patients. Multivariate analysis indicated that an
Table 5. Multivariate Analysis of Disease-Free Survival for Adult Myelofibrosis Patients Receiving HLA Siblings or Unrelated
Transplants between 1989 and 2002, Reported to the CIBMTR (Patients with Missing Relapsed Data Were Excluded)
Variables N Relative Risk P-Value
Donor
HLA-identical sibling 156 1.00
Unrelated 96 1.32 (0.96-1.83) .0924
Karnofsky performance status
$90 142 1.00
<90 110 1.41 (1.04-1.92) .0284
Blast in peripheral blood prior to transplant
Absent 133 1.00 .0045 (2 df)
Present 86 1.75 (1.24-2.47) .0013
Missing 33 1.53 (0.95-2.48) .0819
Splenomegaly prior to conditioning
No 70 1.00 .5332 (3 df)
Yes 106 0.81 (0.56-1.17) .2508
Splenectomy 58 0.77 (0.49-1.21) .2573
Missing 18 1.03 (0.56-1.90) .9228
Fibrosis in marrow prior to conditioning (osteomyelosclerosis)
No 74 1.00 .1352 (2 df)
Yes 79 1.52 (1.01-2.29) .0455
Missing 99 1.28 (0.86-1.91) .2292
CIBMTR indicates Center for International Blood and Marrow Transplant Research.
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or greater, and absence of PB blasts predicted for supe-
rior DFS. Patients transplanted with a URD, poor
Karnofsky score, and presence of blasts in PB did
worse with a 15% 3-year DFS. Small patient numbers
precluded further analysis as to unrelated donor match
and survival. Guardiola and others [15] also identified
high pretransplant hemoglobin and the absence of
grade III fibrosis as positive predictors of survival.
The issue of splenectomy prior to transplant is con-
troversial [29]. Li and colleagues [32] showed faster
neutrophil engraftment (18 versus 23 days) for 26 pa-
tients receiving high-dose conditioning and allogeneic
HCT. However, an operative mortality rate of up to
8%has also been reported [33,34]. In our series, approx-
imately 25% of patients had received a splenectomy
prior to transplant. Splenectomy did not predict for bet-
ter survival;, however, the study was not designed to test
this particular issue. The graft failure was high in pa-
tients receiving URD and alternative donor transplants,
but was not influenced by splenomegaly.
Point mutation in the JAK-2 gene is now reported
in approximately 50% to 60% of patients with myelo-
fibrosis. The significance of the mutation for long-
term outcomes posttransplant is unknown. Kroger
and colleagues [35] reported on 41 patients receiving
allogeneic transplantation for myelofibrosis; 51%
were positive for the V617F point mutation in JAK2.
Seventy-eight percent of patients became JAK2 muta-
tion-negative after a median of 89 days after HCT.
Clinical trials with oral JAK2 kinase inhibitors are in
progress.
Recently, several investigators have analyzed re-
sults of transplantation using RIC regimens [36-39].
RIC regimens may be appropriate for a disease suchas myelofibrosis, because of the older age of the pop-
ulation. Kroger and colleagues [35] treated 24 pa-
tients with myelofibrosis with a conditioning
regimen of Flu, Bu, and antithymocyte globulin
(ATG), followed by related donor (n 5 6) or URD
(n 5 18) transplantation [20]. There were no graft
failures and no 100-day TRM. At 3 years, the esti-
mated DFS was 84%. Seventy-eight percent of
JAK2 kinase mutated patients became PCR negative
for the JAK2 mutation. Rondelli et al. [19] reported
on another cohort of 21 patients treated with a variety
of fludarabine-based reduced intensity regimens.
DFS was 74% at 3 years. The Swedish group reported
on 27 patients: 17 with an MA regimen, and 10 with
an RIC regimen [40]. As expected, TRM was less in
the patients receiving an RIC regimen (10% versus
30%). With a median follow-up of 55 months, 9 of
10 RIC patients and 9 of 16 MA patients are alive.
In our series, 60 patients were treated with NMA or
RIC regimens. The TRM at 1 year was lower for
HLA-identical sibling recipients of HCT using RIC
regimens, but remained high in URD recipients.
RICHLA-identical siblingHCTmay be an attractive
option for older patients with myelofibrosis, and
should be the subject of further study in large cohorts
of patients; a prospective international trial will be ad-
dressing this issue.
This analysis suggests that allogeneic HCT for
myelofibrosis is being performed in many centers
worldwide, with long-term survival rates of 30% to
40%, depending on donor source. Several investiga-
tors have examined prognostic factors to guide the
timing of transplantation [41,42]. Future research
will focus on the selection of the appropriate patients,
conditioning regimen, and timing of transplantation.
Figure 4. DFS probability of adult patients receiving HLA-identical sib-
ling HCT by different risk groups for myelofibrosis reported to the
CIBMTR between 1989 and 2002.
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